이퀼리움 (EQ) 주가

이퀼리움(EQ)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.92 (+1.59%), 시가총액 $137.83M, 52주 범위 $0.29 ~ $2.59.

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

핵심 지표

• 현재가: $1.92 (+1.59%)
• 시가총액: $137.83M
• 52주 최저~최고: $0.29 ~ $2.59
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

이퀼리움의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

이퀼리움 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 보유 (3.0 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 4.67
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문